Loading clinical trials...
Loading clinical trials...
Clinical Trial Optimizing Tumor Ablation for Liver Metastases: Rapid Tissue Analysis Allowing for Immediate Retreatment; Metabolic Imaging Biomarker Validation; and Predictive Genetic Signatures
Conditions
Interventions
[18-F]- FDG - PET
Tumor ablation (TA)
+1 more
Locations
1
United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Start Date
October 25, 2019
Primary Completion Date
October 1, 2026
Completion Date
October 1, 2026
Last Updated
March 19, 2026
NCT06362395
NCT06787183
NCT07281924
NCT07225036
NCT07177742
NCT07224724
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions